Successful autologous stem cell collection in patients with chronic myeloid leukemia in complete cytogenetic response, with quantitative measurement of BCR-ABL expression in blood, marrow, and apheresis products

Leukemia and Lymphoma

Volumn 49, Issue 3, 2008, Pages 531-537

  Gordon, Melinda K ^a   Sher, Dorie ^a   Karrison, Theodore ^a   Kebriaei, Partow ^a   Chuang, Karen ^a   Zhang, Yanming ^a   McDonnell, Diane ^a   Artz, Andrew ^a   Godley, Lucy ^a   Odenike, Olatoyosi ^a   Rich, Elizabeth ^a   Michaelis, Laura ^a   Thirman, Michael J ^a   Wickrema, Amittha ^a   Van Besien, Koen ^a   Larson, Richard A ^a   Stock, Wendy ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

Autologous stem cell mobilization; BCR ABL; Chronic myeloid leukemia; Imatinib mesylate; Minimal residual disease

Indexed keywords

BCR ABL PROTEIN; CD34 ANTIGEN; CYTARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; HOMOHARRINGTONINE; IMATINIB; INTERFERON; RETINOIC ACID;

ADOLESCENT; ADULT; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BLOOD; BLOOD ANALYSIS; BONE MARROW; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOGENETICS; DRUG DOSE INCREASE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REPEATED DRUG DOSE; STEM CELL MOBILIZATION; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; ANTIGENS, CD34; BLOOD COMPONENT REMOVAL; BONE MARROW; CYTOGENETIC ANALYSIS; FEMALE; FILGRASTIM; FUSION PROTEINS, BCR-ABL; HEMATOPOIETIC STEM CELL MOBILIZATION; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; PIPERAZINES; PYRIMIDINES; REMISSION INDUCTION; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 39749131562     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190701799043     Document Type: Article

References (22)

1. Druker, B. J., Talpaz, M., Resta, D. J., Peng, B., Buchdunger, E. and Ford, J. M. (2001) Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N EngI J Med, 344, pp. 1031-1037.
2. O'Brien, S. G., Guilhot, F., Larson, R. A., Gathmann, I., Baccarani, M. and Cervantes, F. (2003) Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med, 348, pp. 994-1004.
3. Kantarjian, H. M., Cortes, J. E., O'Brien, S., Giles, F., Garcia-Manero, G. and Faderl, S. (2003) Imatinib mesylate therapy in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia: High incidence of early complete and major cytogenetic responses. Blood, 101, pp. 97-100.
4. Press, R. D., Love, Z., Tronnes, A. A., Yang, R., Tran, T. and Mongoue-Tchokote, S. (2006) BCR-ABL mRNA levels at and after the time of a complete cytogenetic response (CCR) predict the duration of CCR in imatinib mesylate-treated patients with CML. Blood, 107, pp. 4250-4256.
5. Reiffers, J., Goldman, J., Meloni, G., Cahn, J. Y. and Gratwohl, A. (1994) Autologous stem cell transplantation in chronic myelogenous leukemia: A retrospective analysis of the European Group for Bone Marrow Transplantation. Chronic Leukemia Working Party of the EBMT. Bone Marrow Transplant, 14, pp. 407-410.
6. Deisseroth, A. B., Zu, Z., Claxton, D., Hanania, E. G., Fu, S. and Ellerson, D. (1994) Genetic marking shows that Ph+ cells present in autologous transplants of chronic myelogenous leukemia (CML) contribute to relapse after autologous bone marrow in CML. Blood, 83, pp. 3068-3076.
7. Martinelli, G., Montefusco, V., Amabile, M., Lemoli, R. M., Terragna, C. and Testoni, N. (2000) Quantitative evaluation of BCR-ABL amount of transcript post mobilization with G-CSF of peripheral blood stem cells from chronic myeloid leukemia patients in cytogenetic response. Leuk Lymphoma, 39, pp. 113-120.
8. Gordon, M. K., Kebriaei, P., Sher, D., Bennett, D., Larson, R. A. and Stock, W. (2003) Autologous stem cell collection and measurement of minimal residual disease in patients with chronic myeloid leukemia (CML) treated with imatinib mesylate. Blood (Suppl.), 102, p. 953a.
9. Stock, W., Yu, D., Karrison, T., Sher, D., Stone, R. M. and Larson, R. A. (2006) Quantitative real time RT-PCR monitoring of BCR-ABL in CML shows lack of agreement in blood and bone marrow samples: Cancer and Leukemia Group B study 29801. Int J Oncol, 28, pp. 1099-1103.
10. Beillard, E., Pallisgaard, N., van der Velden, V. H., Bi, W., Dee, R. and van der Schoot, E. (2003) Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using 'real-time' quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) - a Europe against cancer program. Leukemia, 17, pp. 2474-2486.
11. Agis, H., Jaeger, E., Doninger, B., Sillaber, C., Marosi, C. and Drach, J. (2006) In vivo effects of imatinib mesylate on human haematopoietic progenitor cells. Eur J Clin Invest, 36, pp. 402-408.
12. Hui, C. H., Goh, K. Y., White, D., Branford, S., Grigg, A. and Seymour, J. F. (2003) Successful peripheral blood stem cell mobilisation with filgrastim in patients with chronic myeloid leukaemia achieving complete cytogenetic response with imatinib, without increasing disease burden as measured by quantitative real-time PCR. Leukemia, 17, pp. 821-828.
13. Drummond, M. W., Marin, D., Clark, R. E., Byrne, J. L., Holyoake, T. L. and Lennard, A. (2003) Mobilization of Ph chromosome-negative peripheral blood stem cells in chronic myeloid leukaemia patients with imatinib mesylate-induced complete cytogenetic remission. Br J Haematol, 123, pp. 479-483.
14. Kreuzer, K. A., Kluhs, C., Baskaynak, G., Movassaghi, K., Dorken, B. and Coutre, P le (2004) Filgrastim-induced stem cell mobilization in chronic myeloid leukaemia patients during imatinib therapy: Safety, feasibility and evidence for an efficient in vivo purging. Br J Haematol, 124, pp. 195-199.
15. Iacobucci, I., Saglio, G., Rosti, G., Testoni, N., Pane, F. and Amabile, M. (2006) Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients. Clin Cancer Res, 12, pp. 3037-3042.
16. Gabert, J., Beillard, E., van der Velden, V. H., Bi, W., Grimwade, D. and Pallisgaard, N. (2003) Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program. Leukemia, 17, pp. 2318-2357.
17. Hughes, T., Deininger, M., Hochhaus, A., Branford, S., Radich, J. and Kaeda, J. (2006) Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: Review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood, 108, pp. 28-37.
18. Talpaz, M., Shah, N. P., Kantarjian, H., Donato, N., Nicoll, J. and Paquette, R. (2006) Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med, 354, pp. 2531-2541.
19. Kantarjian, H., Giles, F., Wunderle, L., Bhalla, K., O'Brien, S. and Wassmann, B. (2006) Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med, 354, pp. 2542-2551.
20. Kerkela, R., Grazette, L., Yacobi, R., Iliescu, C., Patten, R. and Beahm, C. (2006) Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med, 12, pp. 908-916.
21. Wetzler, M., Stock, W., Owzar, K., Sher, D. A., Hoke, E. E. and Linker, C. A. (2006) Sequential imatinib and chemotherapy yield reverse-transcriptase polymerase chain reaction (RT-PCR)-negative peripheral stem cell collections in Philadelphia (Ph) chromosome positive acute lymphoblastic leukemia (ALL) - preliminary results of CALGB 10001. J Clin Oncol ASCO Ann Meet Proc, 24, p. 6549.
22. Ferrara, F., Palmieri, S., Annunziata, M., Pocali, B., Viola, A. and Pane, F. (2004) Prolonged molecular remission after autologous stem cell transplantation in relapsed acute promyelocytic leukemia. Haematologica, 89, pp. 621-622.